Archives
What Multiplex CRISPR Comparisons Really Show
2026-11-17
Published comparisons support multiplex CRISPR–Cas as a flexible framework for coordinated genetic perturbation, but they also show that editing efficiency, structural outcomes, specificity, delivery, and cellular fitness are distinct evidence layers. The strongest conclusions concern capability; therapeutic and product-level claims remain more conditional.
Multiplex CRISPR: What the Evidence Shows
2026-11-16
Multiplex CRISPR can connect simultaneous genomic perturbations to gene function, structural variation and cell-state outcomes, but its strongest evidence is still platform-level rather than product- or model-specific. The central interpretive issue is separating intended editing from downstream consequences such as DNA-damage toxicity, off-target modification and complex rearrangement. A recent review supports the technology’s breadth while emphasizing unresolved constraints in specificity, delivery, accessibility and clinical translation.
What Multiplexed CRISPR Evidence Actually Shows
2026-11-16
A literature-focused analysis of how multiplexed CRISPR–Cas editing expands the questions researchers can ask while introducing distinct risks involving structural variation, off-target activity, delivery, and cellular damage. The article separates direct genome-editing readouts from downstream biological effects and assesses what the reviewed evidence can—and cannot—establish about translation.
Multiplex CRISPR: Evidence and Limits
2026-11-15
A literature-focused analysis of how multiplex CRISPR–Cas editing expands genome engineering while increasing concerns about structural variation, cellular damage, delivery, specificity and clinical transferability.
Multiplex CRISPR: Mechanism, Evidence and Limits
2026-11-14
Multiplex CRISPR changes genome editing from isolated locus perturbation into a problem of coordinated DNA repair, network biology and measurement interpretation. The strongest evidence supports programmable multi-site perturbation, while structural variation, off-target activity, cellular stress and delivery remain important boundaries on how broadly the findings can be applied.
What the Rabbit Pharming Study Actually Shows
2026-11-13
Song et al. present a proof of concept for targeted rabbit pharming in which a tdTomato reporter was inserted at the endogenous CSN2 locus and expressed under the β-casein regulatory environment. The reported 15–20 g/L milk concentration is a substantial result, but its interpretation is limited by the small number of producing animals, the use of a fluorescent reporter rather than a therapeutic protein, and the absence of a matched head-to-head comparison with conventional transgenesis.
How U1 Promoters Redirect Cas13 Guides
2026-11-13
A literature-focused analysis of how U1 promoter-driven CRISPR RNAs alter intracellular guide localization and expand Cas13-mediated RNA regulation, with attention to mechanism, readouts, evidence strength, and applicability limits.
Multiplex CRISPR: Mechanism, Evidence and Limits
2026-11-12
Multiplex CRISPR can expose genetic interactions and generate large genomic rearrangements by coordinating several targeted DNA perturbations. The strongest evidence supports its value as a mechanistic research platform, while the same repair processes create uncertainty around structural variation, cellular stress, specificity and clinical translation.
Multiplex CRISPR: What the Evidence Shows
2026-11-12
A literature-focused examination of how multiplexed CRISPR–Cas editing produces combinatorial gene perturbations and structural variation, while weighing off-target effects, cellular damage, delivery constraints, and the limits of translating review-level evidence into specific cell models.
What Multiplex CRISPR Evidence Really Shows
2026-11-11
A literature-focused analysis of how multiplexed CRISPR–Cas editing enables combinatorial gene perturbation, structural-variant modeling and epigenetic regulation, while highlighting unresolved concerns about DNA-damage burden, off-target activity, delivery and clinical transferability.
PET and mRNA Antigen Expression: What the Signal Means
2026-11-11
A reporter-based PET strategy addresses a central measurement problem in mRNA therapeutics: separating delivery and RNA persistence from the production of encoded protein. The evidence supports a promising preclinical readout, while reporter biology, tracer kinetics, formulation dependence and clinical relevance remain important interpretive boundaries.
How Condensate Coronas Transfer Biomolecules
2026-11-10
A 2026 Nature Materials study describes a rare class of nanoparticle–cell hybrids in which a cell-derived biomolecular condensate corona enables the export and intercellular transfer of proteins and RNA. The evidence supports a mechanism involving condensate acquisition, selective trafficking, endosomal separation and intracellular redistribution, while leaving the frequency, physiological relevance and generality of the process unresolved.
How Condensate Coronas Move RNA Between Cells
2026-11-10
A literature-focused analysis of how rare nanoparticle–condensate complexes acquire cellular proteins and RNAs, escape endo-lysosomal processing, and transfer functional biomolecules between cells, with emphasis on mechanism, comparators, evidence strength, and limitations.
Multiplex CRISPR: Evidence, Mechanism, Limits
2026-11-09
Multiplex CRISPR–Cas editing can interrogate interacting genes, create defined structural variation, and combine transcriptional or epigenetic perturbations. The strongest evidence supports its value as a research platform, while delivery, off-target activity, DNA-damage toxicity, and model dependence continue to limit direct clinical generalization.
How Condensate Coronas Move RNA Between Cells
2026-11-09
A mechanistic analysis of how rare nanoparticle–condensate complexes acquire cellular biomolecules, escape conventional endosomal processing and transfer functional RNA-related cargo between cells.